Abstract:Objective To explore the incidence of insulin resistance (IR) in patients with obese polycystic ovary syndrome (PCOS) and its relationship with body composition including body fat (BF) and visceral fat area (VFA).Methods In the period from April 2013 to December 2014, in Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, 62 patients with obese PCOS who were in the weight loss program in the Department of Clinical Nutrition were selected, and 19 obesity subjects without PCOS, matching with the obsess PCOS group in age and body mass index (BMI), were selected as controls.In the cases and controls, we used Biospace Inbody720 body composition analyzer to determine their body composition, measured serum lipid profile, conducted 75 g oral glucose tolerance test and insulin release test, and calculated homeostasis model assessment of insulin resistance (HOMA-IR).Results Blood lipids, insulin level, and HOMA-IR were not significantly different between the obese PCOS and the control groups (all P ＞ 0.05).Both groups showed IR (defined as HOMA-IR≥2.69), and HOMA-IR in the obese PCOS group was higher than that in the control group, but with no significant difference (6.17 ± 3.15 vs.5.00 ±2.18, t =1.515, P =0.134).The mean alanine aminotransferase (ALT) level in the obese PCOS group was higher than normal, and the ALT values and the proportion of patients with ALT ＞ 40 U/L were higher than those in the control group, but with no significant difference (P =0.106 and P =0.134).Those with nonalcoholic fatty liver disease (NAFLD) accounted for 27/62 in the obese PCOS group, also higher than the 6/19 in the control group (x2 =0.863, P =0.353).BF in the obese PCOS group was lower than that in the control group [(36.28±6.16) kgvs.(39.56±6.13) kg, t=-2.032, P=0.046], so was VFA after adjusting for waist-to-hip ratio [(150.39 ± 22.86) cm2 vs.(161.74 ± 20.77) cm2, OR =0.963, P =0.040].Linear regression analysis showed that HOMA-IR was not correlated with BF, VFA or other body composition indexes in the obese PCOS patients (all P ＞ 0.05).Conclusions Obesity PCOS patients have significant IR, but HOMA-IR seems to be not correlated with BF, VFA, and other body composition indexes in this population.Studies with larger sample size and exploring relevant mechanisms are still needed.

Homeostasis model assessment-insulin resistance (HOMA-IR), a key role for assessing the ovulation function in polycystic ovary syndrome (PCOS) patients with insulin resistance

Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria

The cut-off value for HOMA-IR discriminating the insulin resistance based on the SHBG level in women with polycystic ovary syndrome

Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance

Association of HOMA-IR with unexpected poor ovarian response in non-obese women in poseidon 1: a retrospective cohort study

Independent and Joint Effects of Β-Cell Dysfunction and Insulin Resistance on Reproductive Outcomes of IVF Cycles in Infertile PCOS Patients

Insulin resistance and its correlation with body composition in patients with obese polycystic ovary syndrome

Ovarian Sensitivity Decreased Significantly in Patients With Insulin Resistance Undergoing in vitro Fertilization and Embryo Transfer

Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population

Association of anti-Müllerian hormone and insulin resistance in adolescent girls with polycystic ovary syndrome

Dyslipidemia in Relation to Body Mass Index and Insulin Resistance in Chinese Women with Polycystic Ovary Syndrome.

Insulin resistance and β-cell dysfunction and the relationship with cardio-metabolic disorders among women with polycystic ovary syndrome

Association of obesity and hyperandrogenemia with insulin resistance in women with polycystic ovary syndrome

Effect of Hyperinsulinemia and Insulin Resistance on Endocrine, Metabolic, and Reproductive Outcomes in Non-PCOS Women Undergoing Assisted Reproduction: A Retrospective Cohort Study

Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment

Serum Anti-Müllerian Hormone and Insulin Resistance in the Main Phenotypes of Non-Obese Polycystic Ovarian Syndrome Women in China.

Insulin Resistance is a Risk Factor for Early Miscarriage and Macrosomia in Patients With Polycystic Ovary Syndrome From the First Embryo Transfer Cycle: A Retrospective Cohort Study

Therapeutic Effect of Metformin on Patients with Polycystic Ovary Syndrome with Normal Insulin Sensitivity: A Retrospective Study

Effect of irisin on ovarian phosphatidylinositol‐3‐kinase/protein kinase B signaling pathway and mitogen‐activated protein kinase/extracellular signal‐regulated kinase pathways of rats with polycystic ovary syndrome

Anti-Müllerian Hormone Accelerates Pathological Process of Insulin Resistance in Polycystic Ovary Syndrome Patients

Insulin Resistance Adversely Affect IVF Outcomes in Lean Women Without PCOS